Aethlon Medical Announces Presentation Of Hepatitis-C (HCV) Clinical Data At 42nd Annual American Society Of Nephrology (ASN) Conference

Main Category: Liver Disease / Hepatitis
Also Included In: Urology / Nephrology;  Clinical Trials / Drug Trials;  Conferences
Article Date: 16 Oct 2009 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:3 stars

3 (2 votes)

Healthcare Prof:not yet rated


Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr. Vijay Kher, principal investigator of the Hemopurifier® studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier® treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Center in San Diego, California.

"We are honored that Dr. Kher has been invited to travel from India to present our clinical data at the largest annual gathering of Nephrologists," stated Aethlon Chairman and CEO, Jim Joyce. The Aethlon Hemopurifier® is the first-in-class medical device able to selectively remove viruses and immunosuppressive proteins from the bloodstream. In HCV care, the device targets to improve patient cure rates as an adjunct to accelerate and enhance the performance of current and future iterations of standard of care drug therapy.

About ASN

More than 11,000 physicians and scientists, all committed to preventing kidney disease and making life better for patients, work together as members of the American Society of Nephrology (ASN). Whether providing expert care to patients, performing cutting-edge medical research, or training the next generation of kidney experts, these nephrologists change lives. Through advocacy, ASN informs policymakers about issues of importance to kidney doctors and their patients. ASN also funds research, convenes world-renowned meetings and generates educational tools that enable nephrologists to be most effective. Building on a 40-year history, ASN brings rigor, integrity, and ingenuity to all its work.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Source: Aethlon Medical, Inc

Article adapted by Medical News Today from original press release.
Visit our liver disease / hepatitis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Aethlon Medical, Inc. "Aethlon Medical Announces Presentation Of Hepatitis-C (HCV) Clinical Data At 42nd Annual American Society Of Nephrology (ASN) Conference." Medical News Today. MediLexicon, Intl., 16 Oct. 2009. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/167569.php>

APA
Aethlon Medical, Inc. (2009, October 16). "Aethlon Medical Announces Presentation Of Hepatitis-C (HCV) Clinical Data At 42nd Annual American Society Of Nephrology (ASN) Conference." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/167569.php.

Please note: If no author information is provided, the source is cited instead.


Liver Disease / Hepatitis

Most Popular Articles



Follow Our Liver Disease News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Liver Disease / Hepatitis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »